News

Life Sciences

Verrica (VRCA) Shows Positive Phase 3 Results in Molluscum Contagiosum at AAD Annual Meeting

Verrica (VRCA) Shows Positive Phase 3 Results in Molluscum Contagiosum at AAD Annual Meeting

Edward Kim | Equities.com |

Two Phase 3 trials show positive results in treating this highly contagious skin disease that affects 6 million people in the US, many of whom are children.


Ocular Therapeutix (OCUL) Doses First Patient in Phase 1 Macular Degeneration Trial

Edward Kim | Equities.com |

OCUL testing tyrosine kinase inhibitor implant for wet age-related macular degeneration (AMD)


Stealth BioTherapeutics Raises $78 Million in IPO for Mitochondrial Diseases

Edward Kim | Equities.com |

Dysfunctional mitochondria characterize many rare genetic and common age-related diseases.


On Valentine's Day, We Examine Advances in Heart Research via Data Analytics and AI

Edward Kim | Equities.com |

Advances in genomics, artificial intelligence and software may help predict and reduce cardiovascular risk


Ortho Regenerative Technologies Begins Final Animal Studies in Rotator Cuff Repair

Edward Kim | Equities.com |

Biopolymer designed to increase healing rates of sports related injuries to tendons, meniscus, ligaments and cartilage.


Seres Therapeutics Refocuses Microbiome Pipeline and Cuts Staff

Edward Kim | Equities.com |

Focusing resources on ulcerative colitis, C. difficile infection and a planned immuno-oncology study.


University of Alberta Researchers Identify a New Gene that Causes Glaucoma

Edward Kim | Equities.com |

We're following several companies pursuing next generation glaucoma treatments.


5 Small Cap Biotechs in Focus on World Cancer Day

Edward Kim | Equities.com |

Each year on February 4th, World Cancer Day empowers all of us to show support, raise our collective voice, take personal action and press our governments to do more.


Eyenovia Shows Positive Phase 3 Results in Pupil Dilation Device

Edward Kim | Equities.com |

80 million annual exams in the US involve mydriasis (pupil dilation)


Voyager Therapeutics Signs Deal with Neurocrine for Parkinson's Disease and Friedreich's Ataxia

Edward Kim | Equities.com |

Voyager gets $165 million upfront + up to $1.7 billion in potential milestone payments